Stifel Reiterates Buy Rating on Relay Therapeutics (RLAY)
Tweet Send to a Friend
Stifel analyst Bradley Canino reiterated a Buy rating and $28.00 price target on Relay Therapeutics (NASDAQ: RLAY).The analyst commented: "Exiting ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


